Melanotan

[sKadoodles Junior Member Find all posts View Profile Close sKadoodles]

Has anyone heard of Melanotan 1 and 2 or the Melanotan II NASAL SPRAY?

[Dbolli Senior Member Find all posts View Profile Close Dbolli]

Yes its pretty cheap. Its a peptide that increases hormones to make you get tanner faster. Research shows it helps prevent sun-exposed skin cancers.

[goanywhere Senior Member Find all posts View Profile Close goanywhere]

I am no expert - but to my reading - injection is much more effective than nasal spray.

For more info - check out http://drugsprofiles.com/growth-horm...anotan-ii.html

[RonnyT Senior Member Find all posts View Profile Close RonnyT]

Completely true!!

I am no expert - but to my reading - injection is much more effective than nasal spray.

For more info - check out http://drugsprofiles.com/growth-horm...anotan-ii.html

http://www.youtube.com/watch?v=AqunZ...eature=related


http://www.youtube.com/watch?v=kpQSxbf4ZM8

http://www.youtube.com/watch?v=ILSIt...eature=related

http://www.youtube.com/watch?v=vXewr...eature=related

[limo Banned Find all posts View Profile Close limo]

Ronny didn't you have some concerns with this product?? By concerns i mean didn't you mention in a previous thread about this that it can cause skin blemishes to become more prominent while taking it?? And that its still in the trial phases so caution should be taken due to the fact that theres not alot of long term data on this substance because its so new

[RonnyT Senior Member Find all posts View Profile Close RonnyT]

It does have sides, as most things you swallow and inject, but beside the freckels and moles, I think it is safe. It should not be taken on a full stomach especially when you start using it, later you get used to it. The vids on YouTube also mention the sides, also a doctor in the US that believes its safe to use. But what is safe?? It was done in trials, but because it is to be injected to be effective, it can't be marketed.

http://nymag.com/lifestyle/sex/annual/2005/15061/

[RonnyT Senior Member Find all posts View Profile Close RonnyT]

Did look into new developments and Palatin is now opting for sub-Q injections. Palatin has since re-initiated Bremelanotide studies for ED and FSD using a subcutaneous delivery method. On August 12, 2009, the company announced that in a double-blind study of 54 volunteers bremelanotide failed to evoke the hypertensive side effects seen with the nasal delivery system used in prior studies, concluding that "variability of uptake" inherent in intranasal administration of the drug resulted in "increases in blood pressure and gastrointestinal events...primarily related to high plasma levels in [only] a subset of patients" and that subcutaneous administration of the drug circumvented the potential for this side effect. It is now in discussions with the FDA to resume Human Phase 2 studies utilizing subcutaneous administration.

New developments:

ranbury, N.J.-based Palatin has struggled since a clinical delay with bremelanotide in 2007. Last year it cut its 40-person staff in half and implemented a 1-for-10 reverse stock split to regain listing requirements. (See BioWorld Today, Sept. 28, 2010.)
Co-founder, President and CEO Carl Spana said during a conference call Thursday that the offering will allow the company, which ended 2010 with only $3.7 million, to "concentrate on advancing our programs and not to be concerned with doing small capital raises several times per year."
Each of the 23 million units offered consists of one share of common stock; a Series A warrant exercisable for 0.087 of a share of common stock at an initial exercise price of $1 per share; and, a Series B warrant exercisable for 0.913 of a share of common stock at an initial exercise price of $1 per share.
Series A warrants are exercisable immediately upon issuance and expire on the fifth anniversary of the date of issuance. Series B warrants are exercisable beginning one year and one day from the date of issuance, but only if Palatin's stockholders increase the number of its authorized shares of common stock, and expire on the fifth anniversary of the date they first become exercisable, the company said.
Spana emphasized during the call that the company was focusing its bremelanotide development efforts on female sexual dysfunction, which he described as an area of need "and a substantial commercial opportunity." He said the company had submitted a protocol and met with the FDA, and agreed on the protocol and design of an at-home Phase II trial of subcutaneously administered bremelanotide for premenopausal women with female dysfunction. Palatin hopes to start the trial in the second quarter, he said.
The female emphasis represents a tweak in earlier strategy for bremelanotide, which had been progressing well as a compound for erectile dysfunction (ED) when a 2007 meeting with the FDA unveiled safety concerns, specifically a blood pressure increase in certain patients. That delayed the drug's move into Phase III testing as a first-line therapy in the general ED population and caused partner King, of Bristol, Tenn., to bail on the firm's potential $250 million collaboration, returning all rights to Palatin. (See BioWorld Today, Aug. 31, 2007.)
Palatin modified the bremelanotide program, switching to subcutaneous administration from nasal administration, and adding a Phase II trial in female sexual dysfunction.
The company had planned to conduct early this year a Phase II trial in ED patients who fail to respond to existing phosphodiesterase-5 (PDE5) inhibitors such as Viagra (sildenafil, Pfizer Inc.) and Cialis (tadalafil, Eli Lilly and Co.) About one-third of patients prescribed PDE5 inhibitors are considered nonresponders. That study was expected to test bremelanotide as both a monotherapy and as an adjunct to PDE5 inhibitor treatment, but it now appears to have been delayed or shelved in favor of the trial for female sexual dysfunction.
Bremelanotide is in a class of therapies called melanocortin agonists and works through the central nervous system rather than directly on the vascular system, the company said, adding that it may benefit patients nonresponsive to PDE5 inhibitors.
The U.S. erectile dysfunction market has an estimated value of more than $2 billion today and is projected to reach $3 billion in three years, the company said. While statistics for females are not yet well defined, the company said studies showed that approximately 50 million women suffer from female sexual dysfunction, for which there are limited treatment options.
During the call, Palatin CFO Stephen Wills reported on the company's 2011 fiscal year second quarter, which ended Dec. 31. The company had a net loss for the quarter of $1.1 million or 9 cents per basic and diluted share, compared to net income of $4.5 million or 42 cents per basic and diluted share for same quarter the previous year. Revenue for the quarter was $1 million, consisting of $847,000 in grant revenue from the Patient Protection and Affordable Care Act of 2010 and $195,000 in contract revenue from partner AstraZeneca for a collaboration based on Palatin's melanocortin receptor obesity program.

latest due to appetite surpressing side-effect of PT-141 and or MT2

[goanywhere Senior Member Find all posts View Profile Close goanywhere]

Stellar Job Ronny! How much do we pay you? What ever it is - we should double it at least.

[dav1dg90 Senior Member Find all posts View Profile Close dav1dg90]

Stellar Job Ronny! How much do we pay you? What ever it is - we should double it at least.

I agree Ronny T is the man, Thanks for all the great info bro!!!! Much appreciated...

[sKadoodles Junior Member Find all posts View Profile Close sKadoodles]

So when I buy Melanotan 2 is that all i need...?